
RNA Stock Forecast & Price Target
RNA Analyst Ratings
Bulls say
Atrium Therapeutics is compelling because its lead asset ATR 1072 has already cleared IND, entered Corventis, and could provide the first human evidence of myocardial delivery, PRKAG2 knockdown, and repeat-dose tolerability in 2H27. The company’s investment case is strengthened by a focused, genetically defined PRKAG2 population of at least 1,000-2,000 in the U.S., preclinical data showing about 85% cardiac PRKAG2 mRNA reduction in NHPs and meaningful functional rescue in mice, and a balance sheet of $267.8 million in cash plus ~$46.5 million in estimated net proceeds that extends runway through 2028. Upside is further supported by ATR 1086, which showed 100% survival in a severe PLN mouse model and ~80% cardiac PLN mRNA reduction in NHPs, while collaboration milestones and patent coverage into the mid-2040s add capital efficiency and long-duration strategic value.
Bears say
Atrium Therapeutics is a high-risk early clinical-stage biotech with no product revenue, so its value depends entirely on ATR 1072, ATR 1086 and other pipeline assets progressing through costly development, regulatory review and eventual commercialization. Its outlook is weakened by dependence on Avidity/Novartis-controlled RNA-delivery IP and the possibility of competing cardiovascular products, which clouds freedom to operate and reduces the durability of any competitive moat. Fundamental risk is further elevated by uncertain safety in genetically constrained cardiomyopathy populations, possible dilution if cash needs rise, and reimbursement pressure that could limit adoption even if the programs are approved.
This aggregate rating is based on analysts' research of Atrium Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNA Analyst Forecast & Price Prediction
Start investing in RNA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Atrium Therapeutics Inc (RNA) Forecast
RNA Analyst Forecast & Price Prediction
Start investing in RNA
Order type
Buy in
Order amount
Est. shares
0 shares